Prenetics Global (Prenetics Global) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Prenetics Global's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.01.

Prenetics Global's long-term debt to total assets ratio increased from Sep. 2022 (0.01) to Sep. 2023 (0.01). It may suggest that Prenetics Global is progressively becoming more dependent on debt to grow their business.

Prenetics Global LT-Debt-to-Total-Asset Historical Data

The historical data trend for Prenetics Global's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global LT-Debt-to-Total-Asset Chart

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

0.01

0.02

0.01

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial								0.01	0.01	0.01	0.01	0.01

Prenetics Global LT-Debt-to-Total-Asset Calculation

Prenetics Global's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	3.763	/	312.131
	=	0.01

Prenetics Global's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	3.063	/	276.415
	=	0.01

Prenetics Global (NAS:PRE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Prenetics Global LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Prenetics Global's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.